Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing Bell
04 Outubro 2010 - 11:00AM
ADVISORY, Oct. 4, 2010 (GLOBE NEWSWIRE) --
What:
Allos Therapeutics, Inc. (ALTH) will visit the NASDAQ MarketSite
in New York City's Times Square.
In honor of the occasion and in honor of patients with blood
cancers and their families, Dr. Charles Morris, Chief Medical
Officer of Allos Therapeutics, Inc. (ALTH); and Brian Tomlinson,
Director of Programs and Services at the Lymphoma Research
Foundation will ring the NASDAQ Closing Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Tuesday, October 5th, 2010 at 3:50 p.m.- 4:00 p.m.
ET
Contacts:
Allos Therapeutics: Madeline Malia (609) 454-0325
mmalia@allos.com Monique Greer (720) 236-5959 mgreer@allos.com
NASDAQ MarketSite: Robert Madden (646) 441-5045
Robert.Madden@NASDAQOMX.com
Feed Information:
The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on
AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on
Ascent fiber 1623. If you have any questions, please contact Robert
Madden (646) 441-5045.
Radio Feed:
An audio transmission of the Closing Bell is also available from
3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24,
downlink frequency 4180 horizontal. The feed can be found on Ascent
fiber 1623 as well.
Facebook and Twitter
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/nasdaqomx
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx
Webcast:
A live webcast of the NASDAQ Closing Bell will be available
at:
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About Allos Therapeutics, Inc. (ALTH):
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN(R) (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other hematologic malignancies
and solid tumors. Allos retains exclusive worldwide rights to
FOLOTYN for all indications. Allos is headquartered in Westminster,
CO. For additional information, please visit www.allos.com.
About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation's largest
non-profit organization devoted exclusively to funding innovative
lymphoma research and providing people with lymphoma and healthcare
professionals with up-to-date information about this type of
cancer. LRF's mission is to eradicate lymphoma and serve those
touched by this disease.
About NASDAQ OMX: The NASDAQ OMX Group, Inc. is
the world's largest exchange company. It delivers trading, exchange
technology and public company services across six continents, with
approximately 3,600 listed companies. NASDAQ OMX offers multiple
capital raising solutions to companies around the globe, including
its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic,
NASDAQ OMX First North, and the U.S. 144A sector. The company
offers trading across multiple asset classes including equities,
derivatives, debt, commodities, structured products and
exchange-traded funds. NASDAQ OMX technology supports the
operations of over 70 exchanges, clearing organizations and central
securities depositories in more than 50 countries. NASDAQ OMX
Nordic and NASDAQ OMX Baltic are not legal entities but describe
the common offering from NASDAQ OMX exchanges in Helsinki,
Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For
more information about NASDAQ OMX, visit http://www.nasdaqomx.com.
*Please follow NASDAQ OMX on Facebook
(http://www.facebook.com/nasdaqomx) and Twitter
(http://www.twitter.com/nasdaqomx).
NDAQA
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024